Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Protein and peptide therapeutics require parenteral administration, which can be a deterrent
to medication adherence. For this reason, there have been extensive efforts to develop …

Importance The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide
and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Background Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed
to investigate a new formulation of oral semaglutide at higher investigational doses versus …

Obesity is a growing epidemic within the USA. Because weight gain is associated with an
increased risk of developing life-threatening comorbidities, such as hypertension or type 2 …

In its 33 years, ADDR has published regularly on the po5tential of oral delivery of biologics
especially peptides and proteins. In the intervening period, analysis of the preclinical and …

Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as
monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 …

Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …

Abstract Losses of 5–10% or more of initial body weight are associated with improvements
in obesity-related comorbidities. However, attaining and sustaining this level of weight loss …